Evidence map›Paper›PMID 29888014›Full record

ArticleCase reports in immunology2018

Runaway Train: A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas.

Børre Fevang, Unn Merete Fagerli, Hanne Sorte, Harald Aarset, Håkon Hov, Marit Langmyr, Thomas Morten Keil, Ellen Bjørge, Pål Aukrust, Asbjørg Stray-Pedersen and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. A novel splice donor mutation inFrontiers in oncology · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Børre FevangK.G. Jebsen Center for Cancer Immunotherapy and K.G. Jebsen Inflammation Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-6828-0609
Unn Merete FagerliDepartment of Oncology, St. Olav's Hospital, Trondheim, Norway.
Hanne SorteDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Harald AarsetDepartment of Pathology, St. Olav's Hospital, Trondheim, Norway.
Håkon HovDepartment of Pathology, St. Olav's Hospital, Trondheim, Norway.
Marit LangmyrDepartment of Radiology, St. Olav's Hospital, Trondheim, Norway.
Thomas Morten KeilDepartment of Nuclear Medicine, St. Olav's Hospital, Trondheim, Norway.
Ellen BjørgeDepartment of Dermatology, St. Olav's Hospital, Oslo, Norway.
Pål AukrustK.G. Jebsen Center for Cancer Immunotherapy and K.G. Jebsen Inflammation Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Asbjørg Stray-PedersenDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Tobias Gedde-DahlDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOSt Olav's University Hospital · NONorwegian University of Science and Technology · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nuclease Artemis is essential for the development of T-cell and B-cell receptors and repair of DNA double-strand breaks, and a loss of expression or function will lead to a radiosensitive severe combined immunodeficiency with no functional T-cells or B-cells (T-B-SCID). Hypomorphic mutations in the

Identifiers

PMID29888014
PMCPMC5977007
OpenAlexW2803689043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.